Skip to main content
TipRanks
Go Ultimate75% OFF

AB Science SA (ABSCF) AI Stock Analysis

16 Followers
ABSCF

AB Science SA

(Other OTC:ABSCF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthRecent revenue growth indicates that AB Science is expanding its reported business base, even though the scale remains small. If this trend continues, it could improve operating leverage and provide a stronger foundation for funding development activities over the next several quarters.
Negative Factors
Persistent LossesPersistent operating and net losses show that the current business has not reached breakeven and that revenue is not yet sufficient to cover its operating base. Continued losses can limit internally funded development, weaken earnings quality, and prolong dependence on external financing.

AB Science SA (ABSCF) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%ABSCF-11.11%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$82.04M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-7.3
Beta (1Y)
0.07
Revenue Growth
20.84%
EPS Growth
39.94%
Country
US
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

AB Science SA Business Overview & Revenue Model

Company Description

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibit...

AB Science SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ABSCF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:SANFR:SAN73OutperformEUR 105.94B25.315.84%4.66%15.30%-35.58%
FR:IPNFR:IPN71OutperformEUR 13.85B27.0011.33%0.96%13.63%14.45%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:OSEFR:OSE49NeutralEUR 39.50M-0.99-96.73%―-96.25%-197.89%
FR:IPHFR:IPH48NeutralEUR 138.06M-2.42152.56%―-29.48%7.91%
FR:ALCLSFR:ALCLS46NeutralEUR 72.33M-1.68-94.14%―-5.98%-8.67%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%ABSCFFR:IPHFR:IPNFR:OSEFR:SANFR:ALCLSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ABSCF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ABSCFAb Science1.12-0.14-11.11%
FR:IPHInnate Pharma S.A.1.24-0.31-20.26%
FR:IPNIpsen167.4040.4531.86%
FR:OSEOSE Immunotherapeutics1.68-3.74-68.99%
FR:SANSanofi88.325.386.48%
FR:ALCLSCellectis SA1.00-2.58-72.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.